Nkarta, Inc. (NASDAQ:NKTX) Receives $10.75 Consensus Price Target from Analysts

Nkarta, Inc. (NASDAQ:NKTX) has received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $11.20.

Several research analysts have issued reports on NKTX shares. Evercore set a $9.00 price objective on Nkarta in a report on Monday, May 18th. Stifel Nicolaus lowered their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. Wall Street Zen downgraded Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Nkarta in a research note on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a research note on Wednesday, June 24th.

Key Nkarta News

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Nkarta in the 2nd quarter valued at about $17,830,000. GSK plc bought a new stake in shares of Nkarta during the fourth quarter worth approximately $5,829,000. Monaco Asset Management SAM raised its stake in shares of Nkarta by 29.2% during the fourth quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company’s stock worth $4,712,000 after buying an additional 576,022 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Nkarta by 1.8% in the first quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company’s stock valued at $3,655,000 after buying an additional 30,350 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Nkarta by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after buying an additional 10,065 shares during the period. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Up 1.3%

Shares of NASDAQ NKTX opened at $2.33 on Friday. Nkarta has a 1-year low of $1.70 and a 1-year high of $3.72. The company has a 50-day moving average of $2.64 and a two-hundred day moving average of $2.58. The company has a market cap of $166.87 million, a PE ratio of -1.48 and a beta of 0.93.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.18). As a group, equities research analysts forecast that Nkarta will post -1.54 earnings per share for the current year.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.